This paper by the International Myeloma Working Group, reviews the available evidence and provides recommendations for the management of myeloma-related kidney disease
These guidelines, produced by an expert panel on behalf of the European Myeloma Network (EMN), provide recommendations for the management of the most common complications of myeloma, including bone and kidney disease.
Results from a Myeloma UK study, in which myeloma patients participated in a survey to determine individual preferences for treatment outcomes, have been published in The Oncologist. The survey, which was based on multicriteria decision analysis (MCDA) and swing weighting, asked patients to state their preference for the following outcomes of treatment; an increase in…
DetailsAmgen has announced that its Phase III trial, ARROW, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared the effect of giving patients a higher dose of carfilzomib (Kyprolis®) once a week, compared to a smaller dose twice a week, together with dexamethasone. The…
DetailsThe Scottish Medicines Consortium (SMC) has approved the use of daratumumab (Darzalex®) monotherapy as a fourth line treatment option for relapsed and refractory myeloma patients in Scotland, who have previously received treatment with a proteasome inhibitor and immunomodulatory drug. This decision is based on the pooled analysis of results from two clinical trials, MMY2002 and…
DetailsA study, funded by Myeloma UK, has identified a link between overexpression of EZH2 and high risk myeloma. The results, published in the Blood Cancer Journal, demonstrate that patients with high levels of EZH2 expression had shorter overall survival and response to treatment compared to patients with low levels of EZH2 expression, regardless of treatment.…
DetailsPlasma Cell Infiltration of the Kidney as a Manifestation of Myeloma: A Report of Three Cases. Kaur T et al. Indian J Nephrol. 2017 Sep-Oct;27(5):395-398. doi: 10.4103/ijn.IJN_215_16. Incidence of Contrast-Induced Nephropathy in Patients with Multiple Myeloma Undergoing Contrast-Enhanced Procedures. Crowley MP et al. Pathol Oncol Res. 2017 Sep 13. doi: 10.1007/s12253-017-0300-9. [Epub ahead of print]. Multiple Myeloma Presenting as Massive Amyloid Deposition in a Parathyroid…
DetailsInhibition of the deubiquitinase USP5 leads to c-Maf protein degradation and myeloma cell apoptosis. Wang S et al. Cell Death Dis. 2017 Sep 21;8(9):e3058. doi: 10.1038/cddis.2017.450. The non-canonical poly(A) polymerase FAM46C acts as an onco-suppressor in multiple myeloma. Mroczek S et al. Nat Commun. 2017 Sep 20;8(1):619. doi: 10.1038/s41467-017-00578-5. Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase. Dorasamy MS et al. J…
DetailsA recent study, conducted by the International Myeloma Working Group (IMWG), has demonstrated the benefits of whole body computed tomography (WBCT) compared to conventional skeletal survey (CSS) for identifying osteolytic lesions in myeloma. The study, published in Blood Cancer Journal, found that WBCT is more sensitive than CSS in detecting skeletal lesions, with 20-25% patients…
DetailsA study, funded by Myeloma UK, has demonstrated that neutral tumour evolution in myeloma is associated with poorer prognosis. Neutral evolution is the term used to describe evolution caused by random genetic mutations and are normally considered to be neither beneficial nor detrimental to survival. However, in this study, such tumours conferred a worse prognosis…
Details